Granted Patent B2

US 8,168,183 · App. 12/431,661 · Granted May 1, 2012

Abstract

Claims (47)

1. An isolated anti-GM-CSF antibody, comprising:

a V H that has a CDR1 having a sequence NYYIH (SEQ ID NO:25), a CDR2 having a sequence WINAGNGNTKYSQKFQG (SEQ ID NO:27), and a CDR3 having a sequence RQRFPYYFDY (SEQ ID NO:16); and

a V L that has a CDR1 having a sequence RASQSVGTNVA (SEQ ID NO:31) or RASQSIGSNLA (SEQ ID NO:32), a CDR2 having a sequence STSSRAT (SEQ ID NO:33), and a CDR3 having a sequence QQFNKSPLT (SEQ ID NO:18) or QQFNRSPLT (SEQ ID NO:28).

2. The antibody of claim 1 , wherein the J segment comprises YFDYWGQGTLVTVSS (SEQ ID NO:14).

3. The antibody of claim 1 , wherein the V H region comprises a V-segment sequence from a V H region VH#3 (SEQ ID NO:3), VH#4 (SEQ ID NO:4), or VH#5 (SEQ ID NO:5).

4. The antibody of claim 1 , wherein the V H has the sequence of VH#3 (SEQ ID NO:3), VH#4 (SEQ ID NO:4), or VH#5 (SEQ ID NO:5).

5. The antibody of claim 1 , wherein the antibody comprises a human germline JK4 region.

6. The antibody of claim 1 , wherein the V L region CDR3 comprises QQFNKSPLT (SEQ ID NO:18).

7. The antibody of claim 6 , wherein the V L region CDR1 has the sequence RASQSIGSNLA (SEQ ID NO:32).

8. The antibody of claim 1 , wherein the V L region CDR3 comprises QQFNRSPLT (SEQ ID NO:28).

9. The antibody of claim 8 , wherein the V L region CDR1 has the sequence RASQSVGTNVA (SEQ ID NO:31).

10. The antibody of claim 1 , wherein the V L region comprises a V segment sequence from a V L region VK#1 (SEQ ID NO:6), VK#2 (SEQ ID NO:7), VK#3 (SEQ ID NO:8), or VK#4 (SEQ ID NO:9).

11. The antibody of claim 1 , wherein the V L region has the sequence of VK#1 (SEQ ID NO:6), VK#2 (SEQ ID NO:7), VK#3 (SEQ ID NO:8), or VK#4 (SEQ ID NO:9).

12. The antibody of claim 1 , wherein the antibody is an IgG.

13. The antibody of claim 12 , wherein the antibody comprises a heavy chain constant region having the amino acid sequence set forth in SEQ ID NO:11.

14. The antibody of claim 1 , wherein the antibody comprises a kappa light chain constant region having the amino acid sequence set forth in SEQ ID NO:10.

15. The antibody of claim 1 , wherein the V H region or the V L region, or both the V H and V L region amino acid sequences comprise a methionine at the N-terminus.

16. The antibody of claim 1 , wherein the antibody comprises a V H region having a sequence of VH#3 (SEQ ID NO:3), VH#4 (SEQ ID NO:4), or VH#5 (SEQ ID NO:5) and a V L region having a sequence of VK#1 (SEQ ID NO:6), VK#2 (SEQ ID NO:7), VK#3 (SEQ ID NO:8), or VK#4 (SEQ ID NO:9).

17. The antibody of claim 16 , wherein the antibody is an IgG.

18. The antibody of claim 17 , wherein the antibody comprises a heavy chain constant region having the amino acid sequence set forth in SEQ ID NO:11.

19. The antibody of claim 16 , wherein the antibody comprises a kappa light chain constant region having the amino acid sequence set forth in SEQ ID NO:10.

20. The antibody of claim 1 , wherein the antibody has:

a heavy chain and a light chain variable region combination selected from the group consisting of:

a) VH#4 (SEQ ID NO:4), VK#1 (SEQ ID NO:6);

b) VH#4 (SEQ ID NO:4), VK#2 (SEQ ID NO:7;

c) VH#4 (SEQ ID NO:4), VK#3 (SEQ ID NO:8)

d) VH#4 (SEQ ID NO:4), VK#4 (SEQ ID NO:9);

e) VH#5 (SEQ ID NO:5), VK#1 (SEQ ID NO:6);

f) VH#5 (SEQ ID NO:5), VK#2 (SEQ ID NO:7;

g) VH#5 (SEQ ID NO:5), VK#3 (SEQ ID NO:8); and

d) VH#5 (SEQ ID NO:5), VK#4 (SEQ ID NO:9).

21. The antibody of claim 20 , wherein the heavy chain variable region is VH#4 (SEQ ID NO:4) and the light chain variable region is VK#1 (SEQ ID NO:6).

22. The antibody of claim 20 , wherein the heavy chain variable region is VH#4 (SEQ ID NO:4) and the light chain variable region is VK#2 (SEQ ID NO:7).

23. The antibody of claim 20 , wherein the heavy chain variable region is VH#4 (SEQ ID NO:4) and the light chain variable region is VK#3 (SEQ ID NO:8).

24. The antibody of claim 20 , wherein the heavy chain variable region is VH#4 (SEQ ID NO:4) and the light chain variable region is VK#4 (SEQ ID NO:9).

25. The antibody of claim 20 , wherein the heavy chain variable region is VH#5 (SEQ ID NO:5) and the light chain variable region is VK#1 (SEQ ID NO:6).

26. The antibody of claim 20 , wherein the heavy chain variable region is VH#5 (SEQ ID NO:5) and the light chain variable region is VK#2 (SEQ ID NO:7).

27. The antibody of claim 20 , wherein the heavy chain variable region is VH#5 (SEQ ID NO:5) and the light chain variable region is VK#3 (SEQ ID NO:8).

28. The antibody of claim 20 , wherein the heavy chain variable region is VH#5 (SEQ ID NO:5) and the light chain variable region is VK#4 (SEQ ID NO:9).

29. The antibody of claim 20 , wherein the antibody comprises a heavy chain constant region having the amino acid sequence set forth in SEQ ID NO:11.

30. The antibody of claim 29 , wherein the antibody comprises a kappa light chain constant region having the amino acid sequence set forth in SEQ ID NO:10.

31. An isolated anti-GM-CSF antibody comprising a V H region and a V L region, wherein the V H region has the amino acid sequence set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.

32. The isolated antibody of claim 31 wherein the antibody comprises the V H region set forth in SEQ ID NO:5.

33. The isolated antibody of claim 31 wherein the antibody comprises the V H region set forth in SEQ ID NO:4.

34. The isolated antibody of claim 31 wherein the antibody comprises the V H region set forth in SEQ ID NO:3.

35. The isolated antibody of claim 31 wherein the antibody comprises the V H region set forth in SEQ ID NO:2.

36. The isolated antibody of claim 31 wherein the antibody comprises the V H region set forth in SEQ ID NO:1.

Assignments (8)